Stage III breast cancer, also called locally advanced breast cancer, means the disease has grown beyond the breast tissue and reached nearby lymph nodes or chest structures. Treatment at this stage aims to shrink the cancer, remove it, and prevent it from returning, combining multiple approaches to give patients the best possible chance of long-term control and quality of life.

Understanding Treatment Goals in Locally Advanced Disease

When breast cancer reaches stage III, the approach to treatment becomes more complex than in earlier stages. At this point, the cancer has spread beyond the original tumor site and involves nearby lymph nodes or has grown into surrounding tissues like the chest wall or skin. However, it has not yet traveled to distant organs, which means the disease can still be treated with the goal of achieving long-term remission or cure.^[1]

The main goal of treating stage III breast cancer is to eliminate as much of the cancer as possible while preserving the patient’s ability to function normally and maintain their quality of life. Doctors design treatment plans based on many factors, including the exact size and location of the tumor, how many lymph nodes contain cancer cells, whether the tumor has certain biological features like hormone receptors (proteins that respond to estrogen or progesterone) or HER2 receptors (a protein that promotes cancer growth), and the patient’s overall health and personal preferences.^[2]

Treatment decisions are highly individualized. What works for one person may not be the best choice for another, even if their cancers appear similar on the surface. This is because breast cancer behaves differently depending on its molecular characteristics. For example, a tumor that needs estrogen to grow will respond to different drugs than one that has too much HER2 protein on its surface. Understanding these details helps doctors tailor the treatment plan to target the specific weaknesses of each person’s cancer.^[10]

Because stage III breast cancer is considered locally advanced, treatment typically involves a combination of methods rather than relying on a single approach. This might include surgery, radiation, chemotherapy, hormone-blocking medications, or targeted therapies that attack specific cancer cell features. The order in which these treatments are given matters. Sometimes doctors start with drug therapy to shrink the tumor before surgery, making it easier to remove. Other times, surgery comes first, followed by additional treatments to destroy any remaining cancer cells that might be hiding in the body.^[3]

Standard Treatment Approaches

The standard treatment for stage III breast cancer usually combines several methods in a carefully planned sequence. Most patients will receive chemotherapy at some point, often before surgery. This approach, called neoadjuvant chemotherapy, means giving anti-cancer drugs before removing the tumor. The purpose is to shrink the cancer, making it smaller and easier for the surgeon to take out completely. In some cases, the tumor shrinks enough that a woman who would have needed complete breast removal can instead have a lumpectomy, where only the tumor and a small amount of surrounding tissue are removed.^[11]

Chemotherapy for breast cancer typically involves a combination of drugs given through a vein or sometimes in pill form. The most commonly used chemotherapy drugs include doxorubicin, cyclophosphamide, paclitaxel, and docetaxel. These drugs work by damaging the DNA inside rapidly dividing cells, which includes cancer cells but unfortunately also affects some normal cells like those in the hair follicles, digestive system, and bone marrow. This is why chemotherapy often causes side effects such as hair loss, nausea, fatigue, and increased risk of infections. The treatment is usually given in cycles, with rest periods in between to allow the body to recover. A typical chemotherapy plan might last several months.^[3]

After chemotherapy has done its job shrinking the tumor, surgery is usually the next step. The surgeon will remove the cancer along with affected lymph nodes from under the arm. Depending on how large the tumor is and whether it has invaded surrounding tissues, the surgery might be a lumpectomy or a mastectomy, which means removing the entire breast. If the cancer has spread to the chest wall or caused significant changes to the breast skin, mastectomy is more likely to be recommended. Some women choose to have breast reconstruction surgery afterward to rebuild the breast shape, either at the same time as the mastectomy or later.^[2]

Following surgery, most patients with stage III breast cancer will need radiation therapy. This involves using high-energy X-rays directed at the chest area to kill any cancer cells that might remain after the tumor was removed. Radiation is particularly important for locally advanced breast cancer because it reduces the chance of the cancer coming back in the same area. Treatment is typically given five days a week for several weeks. Each session only takes a few minutes, though the planning process beforehand can take longer. Side effects of radiation therapy usually affect the treated area and can include skin redness, soreness, fatigue, and in rare cases, damage to nearby organs like the heart or lungs.^[10]

For women whose tumors have hormone receptors, hormone therapy plays a crucial role in treatment. These drugs work by blocking the body’s natural hormones from feeding the cancer. Tamoxifen is one of the most commonly prescribed hormone therapy drugs and can be used by women before and after menopause. It works by sitting in the estrogen receptor sites on cancer cells, preventing real estrogen from attaching and stimulating growth. Another class of drugs called aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara), are used in women who have gone through menopause. These drugs stop the body from producing estrogen in the first place. Hormone therapy is usually taken for at least five to ten years because it significantly reduces the risk of the cancer returning.^[11]

When breast cancer cells have too much of a protein called HER2 on their surface, doctors use targeted therapy drugs specifically designed to attack this weakness. The most well-known is trastuzumab (Herceptin), which has been used for many years and dramatically improves outcomes for people with HER2-positive breast cancer. It works like a guided missile, attaching to the HER2 protein on cancer cells and marking them for destruction by the immune system. Other HER2-targeted drugs include pertuzumab (Perjeta), which is often given together with trastuzumab and chemotherapy, and ado-trastuzumab emtansine (Kadcyla), which combines the targeting ability of trastuzumab with a chemotherapy drug attached to it. These medications are usually given through an IV infusion every few weeks and can continue for up to a year after the main treatment is finished.^[11]

The side effects of these treatments vary depending on which drugs are used and how each person’s body responds. Chemotherapy side effects are often the most noticeable and can include nausea, vomiting, loss of appetite, mouth sores, and increased susceptibility to infections because of low white blood cell counts. Hair loss is common with many chemotherapy regimens, though the hair grows back after treatment ends. Hormone therapy can cause symptoms similar to menopause, such as hot flashes, night sweats, vaginal dryness, and joint pain. Some women also experience mood changes or mild memory problems. Targeted therapies like trastuzumab can sometimes affect the heart, so doctors monitor heart function regularly during treatment.^[3]

Treatment in Clinical Trials

Beyond the standard treatments that have been approved and are widely used, there is a whole world of experimental therapies being tested in clinical trials. These studies are carefully designed to test whether new drugs or treatment combinations are safe and whether they work better than existing options. For people with stage III breast cancer, participating in a clinical trial might offer access to cutting-edge treatments that aren’t yet available to the general public.

Clinical trials happen in phases. Phase I trials are the earliest stage, where researchers primarily want to find out if a new treatment is safe, what the right dose should be, and what side effects it might cause. These trials usually involve small numbers of patients. Phase II trials test whether the treatment actually works against cancer and continue to monitor safety. These studies involve more patients and provide preliminary evidence of effectiveness. Phase III trials are large studies that compare the new treatment directly against the current standard treatment to see which one works better. If a treatment proves successful in Phase III, it may be approved by regulatory authorities for general use.^[3]

One area of active research involves improving targeted therapies for HER2-positive breast cancer. Newer drugs combine antibodies that target HER2 with powerful chemotherapy drugs attached to them, creating what scientists call antibody-drug conjugates. Fam-trastuzumab deruxtecan (Enhertu) is one such drug that has shown promising results in clinical trials. It works by delivering chemotherapy directly to cancer cells through the HER2 protein doorway, which means more of the drug reaches the cancer and less affects normal cells. Early trial results have shown that this approach can shrink tumors that didn’t respond well to other HER2-targeted treatments.^[11]

For hormone receptor-positive breast cancer, researchers are studying drugs called CDK4/6 inhibitors. These include palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). These drugs work by blocking proteins that cancer cells need to divide and multiply. They are often combined with hormone therapy to make the treatment more effective. Clinical trials have tested these drugs in various settings, including as additional treatment after surgery for high-risk stage III breast cancer. Results have shown that adding CDK4/6 inhibitors to hormone therapy can reduce the chance of cancer returning, though these drugs can cause side effects like low blood counts, fatigue, and digestive problems.^[11]

Another promising area of research involves immunotherapy, which harnesses the body’s own immune system to fight cancer. Unlike targeted therapy that attacks specific proteins on cancer cells, immunotherapy helps immune cells recognize and destroy cancer. One type of immunotherapy being studied for breast cancer works by blocking a protein called PD-L1 that cancer cells use to hide from the immune system. Pembrolizumab (Keytruda) and atezolizumab (Tecentriq) are immune checkpoint inhibitors that have shown particular promise when combined with chemotherapy for triple-negative breast cancer, an aggressive type that doesn’t have hormone receptors or HER2. Clinical trials have demonstrated that adding immunotherapy to chemotherapy can help shrink tumors more effectively in some patients.^[3]

For patients whose breast cancer is driven by mutations in genes called BRCA1 or BRCA2, a class of drugs called PARP inhibitors offers a targeted approach. These drugs, including olaparib (Lynparza) and talazoparib (Talzenna), work by blocking a repair mechanism that cancer cells with BRCA mutations rely on to survive. Clinical trials have shown that PARP inhibitors can be effective in treating BRCA-related breast cancers, particularly when the cancer has spread or returned after initial treatment. These drugs are taken as pills and can cause side effects like nausea, fatigue, and low blood counts, but many people tolerate them better than traditional chemotherapy.^[11]

Some clinical trials are exploring whether drugs can be better tailored to each person’s cancer by looking at specific genetic changes within the tumor. For instance, if a tumor has a mutation in a gene called PIK3CA, which happens in about 40% of hormone receptor-positive breast cancers, a drug called alpelisib (Piqray) might be used. This drug specifically targets the abnormal protein made by the mutated gene. Testing tumors for these kinds of mutations and matching patients to the right targeted therapy is part of an approach called precision medicine. Clinical trials are ongoing to determine the best ways to use this strategy for stage III breast cancer.^[11]

The location and availability of clinical trials vary widely. Major cancer centers and university hospitals often run numerous trials, while smaller community hospitals might have fewer options but can sometimes connect patients to trials happening elsewhere. In countries like the United States, the United Kingdom, and across Europe, there are registries where doctors and patients can search for appropriate trials based on cancer type, stage, and specific features. To be eligible for a trial, patients usually need to meet certain criteria related to their cancer characteristics, previous treatments, and overall health. Trial participation is always voluntary, and patients can withdraw at any time if they choose to do so.^[3]

Most common treatment methods

• Chemotherapy
  • Often given before surgery to shrink tumors in stage III breast cancer, a strategy called neoadjuvant chemotherapy
  • Common drugs include doxorubicin, cyclophosphamide, paclitaxel, and docetaxel, usually given in combination
  • Administered in cycles over several months, allowing the body recovery time between treatments
  • Can cause side effects including hair loss, nausea, fatigue, and increased infection risk due to low blood counts
• Surgery
  • Lumpectomy removes the tumor and a small margin of surrounding tissue, preserving most of the breast
  • Mastectomy involves removing the entire breast and is necessary when cancer has spread extensively
  • Lymph node removal from the underarm area is performed to check for cancer spread and prevent recurrence
  • Breast reconstruction can be performed immediately during mastectomy or delayed until after other treatments are complete
• Radiation therapy
  • Uses high-energy X-rays to kill cancer cells remaining after surgery
  • Typically given five days per week for several weeks
  • Reduces the risk of cancer returning in the chest area
  • Side effects include skin changes in the treated area, fatigue, and rarely damage to nearby organs
• Hormone therapy
  • Tamoxifen blocks estrogen receptors on cancer cells, preventing hormone-driven growth
  • Aromatase inhibitors (anastrozole, exemestane, letrozole) stop estrogen production in postmenopausal women
  • Treatment continues for five to ten years to prevent cancer recurrence
  • Can cause menopausal symptoms like hot flashes, vaginal dryness, and joint discomfort
• Targeted therapy for HER2-positive cancer
  • Trastuzumab (Herceptin) attaches to HER2 protein on cancer cells and marks them for immune system destruction
  • Pertuzumab (Perjeta) is often combined with trastuzumab and chemotherapy for enhanced effectiveness
  • Ado-trastuzumab emtansine (Kadcyla) delivers chemotherapy directly to cancer cells via HER2 targeting
  • Newer antibody-drug conjugates like fam-trastuzumab deruxtecan (Enhertu) are being tested in clinical trials
• CDK4/6 inhibitors
  • Palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) block proteins cancer cells need to divide
  • Used in combination with hormone therapy for hormone receptor-positive breast cancer
  • Clinical trials are testing these drugs as additional treatment after surgery in high-risk stage III disease
  • Side effects include low blood counts, fatigue, nausea, and diarrhea
• Immunotherapy
  • Checkpoint inhibitors like pembrolizumab (Keytruda) and atezolizumab (Tecentriq) help immune cells recognize cancer
  • Showing promise particularly for triple-negative breast cancer when combined with chemotherapy
  • Works by blocking PD-L1 protein that cancer cells use to evade immune detection
  • Being studied in various clinical trial settings for locally advanced breast cancer
• PARP inhibitors
  • Olaparib (Lynparza) and talazoparib (Talzenna) target cancer cells with BRCA1 or BRCA2 mutations
  • Block DNA repair mechanisms that BRCA-mutated cancer cells depend on for survival
  • Taken as oral medication, often better tolerated than traditional chemotherapy
  • Used when genetic testing shows hereditary BRCA mutations in the tumor or patient